RLX - CAS 4425-23-4

RLX (PD 139530) is a PI3K/Akt/FoxO3a signal inhibitor with anticancer activity against tumour cell lines such as colon cancer, inducing sub-G1 arrest and mitochondrial potential loss, thereby inhibiting tumour growth. RLX also exhibits antitussive and anti-asthmatic activity, reducing eosinophils and total lymphocytes in bronchoalveolar lavage (BAL) fluid, and exhibits toxicity toward A549 cells.

Others, PI3K, Akt, FOXO

Others, Apoptosis, Cytoskeletal Signaling, PI3K/Akt/mTOR signaling

4398

0.9981

C13H14N2O

214.26

O=C1C=2C=CC=CC2N=C3N1CCCCC3

-20°C

Ice Packs

Small Compound